Company news
Alkem Laboratories on Monday informed the exchanges that the USDFA has issued two 483 observations for its Baddi facility. The USFDA had conducted an inspection from September 11 to 15, said Alkem...18-09-2017
18-09-2017
Press Release / Media Release
Update on US FDA Inspection at Alkem's Baddi Facility - This is to inform you that US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 11th September, 2017 to 15th September, 2017. In this regard, the Company has received the inspection report which contains two 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures...18-09-2017
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alkem Laboratories Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here09-09-2017
Outcome of AGM
Outcome of the 43rd Annual General Meeting of the Company and Disclosure of Voting Results thereat. This is with reference to the 43rd Annual General Meeting of the Company held today i.e. on Friday, 8th September, 2017 at 10.30 a.m. at Nehru Centre Auditorium, Dr Annie Besant Road, Worli, Mumbai 400 018. Pursuant to Regulation 30 of the SEBI LODR Regulations, we are submitting herewith the details regarding the brief proceedings...08-09-2017
Clarifies on News item
With reference to news in www.moneycontrol.com dated August 23, 2017 quoting "Alkem Labs gets US FDA nod for rhinitis drug, Azelastine Hydrochloride Spray". Alkem Laboratories Ltd has submitted to BSE a copy of Clarification is enclosed.23-08-2017
Clarification sought from Alkem Laboratories Ltd
The Exchange has sought clarification from Alkem Laboratories Ltd on August 23, 2017 with reference to news in www.moneycontrol.com dated August 23, 2017 quoting "Alkem Labs gets US FDA nod for rhinitis drug, Azelastine Hydrochloride Spray"The reply is awaited.23-08-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tushar Kumar17-08-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Singh17-08-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prabhat Narain Singh17-08-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prasid Uno Family Trust16-08-2017